Nasdaq News

(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company, announced updated Phase 1 clinical data for IBI3003 in patients with relapsed or refractory multiple myeloma (R/R MM), presented orally at the 23rd International Myeloma Society (IMS) Annual Meeting 2026

Key PointsVertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance.

Key PointsNvidia, Broadcom, and Advanced Micro Devices (AMD) have taken full advantage of otherworldly enterprise spending on AI-accelerating chips.

Key PointsStocks are soaring, but that also means we could be entering bubble territory.

Key PointsCRISPR Therapeutics has two important data readouts coming up soon.

Key PointsVerizon's dividend yield is very generous.

Key PointsAdvanced Micro Devices (AMD) recently became the latest American public company to amass a $1 trillion valuation, joining 12 others.

Key PointsAlthough the stock market has performed well in 2026, rising inflation and higher interest rates could derail the rally.

Key PointsCurrent estimates say 2027's Social Security COLA will be larger than this year's 2.8% increase.

(RTTNews) - Eli Lilly and Company (LLY) reported that Foundayo 17.2 mg was associated with greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes, based on a new indirect treatment comparison.

Key PointsMicron earned $28.2 billion in GAAP net income in its fiscal third quarter, which ended May 28.

Key PointsThe FOMC kicked off only the fourth rate-hiking cycle of the 21st century on Sept. 16 to combat persistently elevated inflation.

Key PointsNvidia has seen revenue soar in the triple digits thanks to its strength in the GPU market.

(RTTNews) - Tuesday, Eli Lilly (LLY) said Foundayo 17.2 mg showed greater weight loss and A1C reductions than oral semaglutide 25 mg in an indirect treatment comparison involving adults with type 2 diabetes.

(RTTNews) - Novo Nordisk A/S (NVO) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (1276.HK) announced Tuesday that they have entered into an exclusive license agreement for HRS-1596, a Phase 1-ready GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing.

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced that Eiry W. Roberts will return as Chief Medical Officer, effective immediately, succeeding Sanjay Keswani, who will depart the company by mutual agreement.

Key PointsIt has also set an ambitious target for annual dividend raises.

Key PointsThe market is pricing Micron stock as though it assumes the demand wave for memory will fizzle out in the next 12 months.

(RTTNews) - Ascletis Pharma Inc. (1672.HK) reported positive Phase 1 results for ASC50 in plaque psoriasis, with the investigational oral therapy showing a 48.9% placebo-adjusted reduction in PASI score after 28 days of treatment.

Key PointsBoth the Buffett indicator and the Shiller CAPE ratio show that stocks are at historically expensive levels.